SCHEDULE: Psyence Labs Boosts Stake to 49.75% in Psyence Biomedical

Psyence Labs Ltd. has amended its Schedule 13D filing to report an increase in its beneficial ownership of Psyence Biomedical Ltd. common shares to 49.75% following a share-for-share swap.

Summary

• Psyence Labs Ltd. (PsyLabs) has filed an amendment to its Schedule 13D, increasing its beneficial ownership of Psyence Biomedical Ltd. (the Issuer) common shares to 2,643,659, representing approximately 49.75% of the outstanding shares.
• This increase is due to the acquisition of 1,497,500 additional common shares on October 1, 2026, through a Share-for-Share Swap and Nomination Agreement (Swap Agreement) entered into on September 21, 2026.
• The transaction involved a non-cash consideration of US$8,985,000, with PsyLabs issuing 3,473 ordinary shares to a subsidiary of the Issuer at an implied valuation of US$60,000,000 for PsyLabs.
• As a result of this acquisition, PsyLabs may be deemed an affiliate and control person of the Issuer.
• The Swap Agreement includes standstill restrictions that limit PsyLabs' ability to acquire more securities, solicit proxies, form groups, or influence the Issuer's management or board, with certain exceptions for approved transactions.
• PsyLabs intends to review its investment and may take actions such as acquiring additional securities or disposing of existing ones, subject to the agreement's terms and applicable laws.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a significant increase in beneficial ownership and a strategic share swap, though it also introduces new standstill restrictions.

Positives

• Psyence Labs Ltd. has significantly increased its stake in Psyence Biomedical Ltd., now holding 49.75% of the outstanding common shares.
• The acquisition was completed through a non-cash share-for-share swap, valued at US$8,985,000, indicating a strategic alignment and valuation of Psyence Labs at US$60,000,000.
• Psyence Labs now holds a controlling interest, potentially allowing for greater influence over the Issuer's strategic direction.

Negatives

• The acquisition has resulted in significant standstill restrictions for Psyence Labs, limiting its ability to further acquire securities, influence management, or engage in certain transactions without Issuer board approval.
• The additional shares acquired are subject to resale restrictions under U.S. and Canadian securities laws, requiring registration or an available exemption.
• Psyence Labs may be deemed an affiliate and control person of the Issuer, which could lead to increased regulatory scrutiny.

Risks

• The standstill restrictions imposed by the Swap Agreement could limit Psyence Labs' flexibility in managing its investment and responding to market opportunities or challenges.
• Potential for increased regulatory scrutiny due to Psyence Labs' status as an affiliate and control person.
• The resale of acquired shares is subject to securities law limitations, potentially impacting liquidity and exit strategies.

Future Outlook

Psyence Labs Ltd. intends to continuously review its investment in Psyence Biomedical Ltd. and may, from time to time, take actions such as acquiring additional securities, disposing of securities, engaging in hedging transactions, or proposing strategic actions, all subject to the terms of the Swap Agreement and applicable laws.

Management Comments

• The Swap Agreement forms part of a broader strategic and commercial relationship between the Reporting Person and the Issuer.
• The Reporting Person acquired the Subject Shares and the Additional Shares for investment purposes.
• As a result of the issuance of the Additional Shares, the Reporting Person may be deemed to be an affiliate and control person of the Issuer.
• The Reporting Person has acknowledged that, because it may be deemed an affiliate or control person of the Issuer, any resale of the Common Shares may be subject to additional limitations under applicable securities laws.

Industry Context

StockSavvy.ai notes that this filing reflects a significant consolidation of ownership within the biotechnology sector, specifically concerning companies involved in novel therapeutic areas. The share-for-share swap mechanism is a common strategy for aligning interests and facilitating strategic partnerships or acquisitions without immediate cash outlay, though it often comes with stringent control and standstill provisions.

Comparison to Industry Standards

• The percentage of ownership (49.75%) achieved by Psyence Labs Ltd. is substantial and approaches a controlling stake, which is typical in strategic alliances or pre-acquisition phases within the biotech industry.
• The use of a share-for-share swap with a non-cash consideration valued at US$8,985,000 is a standard practice for such transactions, aiming for equitable value exchange.
• The inclusion of comprehensive standstill restrictions is a common feature in agreements where a significant stake is acquired, designed to protect the Issuer's governance and strategic autonomy while the investor reviews its position.

Corporate Governance

Related Party Transactions

• Psyence Labs Ltd. acquired 1,497,500 common shares of Psyence Biomedical Ltd. through a Share-for-Share Swap and Nomination Agreement, involving non-cash consideration valued at US$8,985,000.
• Psyence Labs Ltd. issued 3,473 ordinary shares to Psyence Biomed II Corp. (a subsidiary of Psyence Biomedical Ltd.) as part of the swap.

Stakeholder Impact

• Shareholders of Psyence Biomedical Ltd.: The increased ownership by Psyence Labs Ltd. to nearly 50% could signal a move towards greater control or a potential future acquisition, impacting share value and governance.
• Psyence Labs Ltd. Shareholders: The investment represents a significant stake in Psyence Biomedical Ltd., with potential for future returns but also subject to the risks and restrictions outlined in the agreement.
• Management and Board of Psyence Biomedical Ltd.: The standstill restrictions limit their ability to be influenced or changed by Psyence Labs without board approval, providing a degree of operational stability in the short term.

Next Steps

• Psyence Labs Ltd. will continue to review its investment in Psyence Biomedical Ltd.
• Psyence Labs Ltd. may acquire additional securities or dispose of existing securities.
• Psyence Labs Ltd. may engage in hedging or similar transactions.
• Psyence Labs Ltd. may propose or consider strategic actions related to the Issuer, subject to standstill restrictions.

Key Dates

Recommendation

The filing indicates a significant increase in beneficial ownership and a strategic alignment, which is positive. However, the substantial standstill restrictions limit immediate upside potential and future strategic flexibility for Psyence Labs, warranting a 'hold' position until further developments clarify the long-term implications.

Keywords

Schedule 13D, Psyence Biomedical, Psyence Labs, Share Swap, Beneficial Ownership, Control Person, Standstill Agreement, Securities Acquisition